Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M25.8Revenue $M--Net Margin (%)--Altman Z-Score-8.8
Enterprise Value $M5.1EPS $-0.9Operating Margin %--Piotroski F-Score3
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yY
Price/Book2.110-y EBITDA Growth Rate %-8.7Quick Ratio12.5Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %1.0Current Ratio12.5Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-68.6Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-103.8Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M23.9ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with GALT

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GALTGeorge Soros 2014-06-30 Sold Out -0.01%$10.23 - $14.81
($12.43)
$ 1.08-91%Sold Out0
GALTGeorge Soros 2014-03-31 Buy 0.01%$8.025 - $18.3
($14.02)
$ 1.08-92%New holding48,200
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GALT is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


GALT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Greenberg ArthurDirector 2016-01-05Buy1,666$1.72-37.21view
AMELIO GILBERT FDirector 2015-11-30Sell100$2.1-48.57view
TRABER PETER GPresident & CEO 2015-08-12Buy2,000$2-46view
TRABER PETER GPresident & CEO 2015-06-01Buy4,000$2.53-57.31view
FREEMAN KEVIN DDirector 2015-06-01Buy2,083$2.7-60view
AMELIO GILBERT FDirector 2014-12-15Sell110$3.69-70.73view
Greenberg ArthurDirector 2014-08-19Buy1,000$4.56-76.32view
FREEMAN KEVIN DDirector 2014-08-15Buy1,000$4.7-77.02view
CALLICUTT JACK WCFO 2014-08-14Buy1,000$4.55-76.26view
TRABER PETER GPresident and CEO 2014-08-14Buy4,000$4.46-75.78view

Press Releases about GALT :

Quarterly/Annual Reports about GALT:

    News about GALT:

    Articles On GuruFocus.com
    No related article found.

    More From Other Websites
    Galectin Therapeutics to Present at Upcoming Conferences Jan 28 2016
    Galectin Therapeutics to Present at Upcoming Conferences Jan 28 2016
    Galectin Therapeutics Inc., to Present at Noble Financial Capital Markets' 12th Annual Investor... Jan 14 2016
    Galectin Therapeutics Inc., to Present at Noble Financial Capital Markets’ 12th Annual Investor... Jan 14 2016
    Galectin Therapeutics Appoints Dr. Marc Rubin Chairman of the Board of Directors Jan 08 2016
    Galectin Therapeutics Appoints Dr. Marc Rubin Chairman of the Board of Directors Jan 08 2016
    GALECTIN THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Other... Jan 08 2016
    Galectin Therapeutics Posts "2015-2016, Progress and Possibilities" to Corporate Website Jan 07 2016
    Galectin Therapeutics Posts “2015-2016, Progress and Possibilities” to Corporate Website Jan 07 2016
    GALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 07 2016
    Galectin Therapeutics Announces Dismissals of Federal Securities Class Action and Shareholder... Jan 05 2016
    Galectin Therapeutics Announces Dismissals of Federal Securities Class Action and Shareholder... Jan 05 2016
    GALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 05 2016
    GALECTIN THERAPEUTICS INC Financials Dec 08 2015
    Is Emmis Communications Corporation (EMMS) A Good Stock To Buy? Nov 23 2015
    Galectin Therapeutics Announces Pricing of $9.8 Million Registered Direct Offering Nov 20 2015
    Galectin Therapeutics Announces Pricing of $9.8 Million Registered Direct Offering Nov 20 2015
    GALECTIN THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Nov 20 2015
    Research Underlying Galectin's Development of GR-MD-02 in Cancer Presented at the Society for... Nov 11 2015
    Galectin Therapeutics Reports Third Quarter 2015 Financial Results and Provides Business Update Nov 09 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK